Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Meningioma 2Typical Teratoid Rhabdoid Tumor 1Pinealoma 1Paraganglioma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neoplasms, Neuroepithelial 1Medulloblastoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

dactolisib 2Everolimus 2surufatinib 1spartalizumab 1pasireotide 1ganitumab 1fosbretabulin 1cixutumumab 1TH 302 1PM 00104 1ONC206 1Fentanyl 1CLR1404 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neuroectodermal Tumors, Primitive × ONC206 × Clear all
NCT04541082 2025-12-18

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Jazz Pharmaceuticals

Phase 1 Recruiting
102 enrolled
CNSSarcoma

Typical Teratoid Rhabdoid Tumor, Astrocytoma, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Oligodendroglioma, Pinealoma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡